Bkt140
Bkt140 is a protein pharmaceutical. It is currently being investigated in clinical studies. It is known to target C-X-C chemokine receptor type 4.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 4 | — | — | — | 4 |
| Myeloid leukemia acute | D015470 | C92.0 | 1 | 4 | — | — | — | 4 | |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 1 | 2 | — | — | — | 2 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | — | 2 | — | — | — | 2 | |
| Adenocarcinoma | D000230 | — | 1 | — | — | — | 1 | ||
| Aplastic anemia | D000741 | HP_0001915 | D61.9 | — | 1 | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | D46 | — | 1 | — | — | — | 1 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | — | 1 | — | — | — | 1 | |
| Hodgkin disease | D006689 | C81 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 | ||
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BKT140 |
| INN | motixafortide |
| Description | Bkt140 is a protein pharmaceutical. It is currently being investigated in clinical studies. It is known to target C-X-C chemokine receptor type 4. |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545348 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | DA9G065962 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CXCR4
CXCR4
Organism
Homo sapiens
Gene name
CXCR4
Gene synonyms
NCBI Gene ID
Protein name
C-X-C chemokine receptor type 4
Protein synonyms
CD184, CD184 antigen, chemokine (C-X-C motif) receptor 4, FB22, Fusin, HM89, LAP-3, LCR1, LESTR, Leukocyte-derived seven transmembrane domain receptor, Lipopolysaccharide-associated protein 3, LPS-associated protein 3, neuropeptide Y receptor Y3, neuropeptide Y3 receptor, NPYRL, SDF-1 receptor, seven transmembrane helix receptor, seven-transmembrane-segment receptor, spleen, Stromal cell-derived factor 1 receptor
Uniprot ID
Mouse ortholog
Cxcr4 (12767)
C-X-C chemokine receptor type 4 (P70658)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 235 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more